# Waiting Time for Pulmonary Vein Isolation: A Single-Center Retrospective Cohort Study of Atrial Fibrillation Progression and Complications

**Authors:** Kaspars Kupics, Matīss Linde, Kristīne Jubele, Oskars Kalējs, Natālija Nikrus, Sandis Sakne, Daiņus Gilis, Georgijs Ņesterovičs, Maija Vikmane, Evija Kanačniece, Ieva Ansaberga, Everita Kupriša, Matīss Karantajers, Andrejs Ērglis

PMC · DOI: 10.3390/medicina62020276 · Medicina · 2026-01-28

## TL;DR

Longer waiting times for a heart procedure called pulmonary vein isolation are linked to worsened heart rhythm problems and more hospital visits.

## Contribution

This study identifies a direct link between extended waiting times for PVI and atrial fibrillation progression.

## Key findings

- 25.7% of patients experienced atrial fibrillation progression during the waiting period.
- Longer waiting times independently increased the risk of AF progression (OR, 1.017 per month).
- Class IC antiarrhythmic therapy reduced the risk of AF progression (HR 0.78).

## Abstract

Background and Objectives: Pulmonary vein isolation (PVI) is an established rhythm control strategy for atrial fibrillation (AF). In many healthcare systems, increasing demand and limited procedural capacity have resulted in prolonged waiting times. The primary aim of this study was to evaluate the association between waiting time for PVI and AF progression. Secondary aims were to assess the relationship between waiting time and AF-related complications, healthcare utilization, and clinical factors associated with higher risk of progression. Materials and Methods: We performed a single-center observational cohort study of patients on the waiting list for PVI at Pauls Stradiņš Clinical University Hospital between 2016 and 2023. Results: A total of 341 patients completed structured ambulatory follow-up to assess the complication and progression rates of AF. The mean age was 64.8 ± 10.5 years, 50.9% were male, and the median waiting time was 37.2 months (IQR 15.0–61.3). AF progression occurred in 25.7% (n = 88) of patients, with longer waiting time independently associated with progression (OR, 1.017 per month; 95% CI, 1.006–1.028; p < 0.05). Electrical cardioversion during the waiting period was associated with a lower likelihood of progression (OR, 0.32; p = 0.029), and Class IC antiarrhythmic therapy was associated with reduced risk of AF progression (HR 0.78; p = 0.013). During follow-up, 45.2% of patients were hospitalized for AF paroxysms, 29.6% underwent electrical cardioversion, and 13.5% experienced complications including stroke and heart failure decompensation. Left atrial volume index and left ventricular ejection fraction were inversely correlated (ρ = −0.355, p < 0.05), but neither was associated with waiting time. Conclusions: Longer waiting times for PVI are associated with AF progression and substantial interim healthcare utilization due to complications. Strategies to prioritize higher-risk patients may help prevent disease progression and reduce complication burden.

## Linked entities

- **Diseases:** atrial fibrillation (MONDO:0004981), stroke (MONDO:0005098), heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** BMP10 (bone morphogenetic protein 10) [NCBI Gene 27302], BCHE (butyrylcholinesterase) [NCBI Gene 590] {aka BCHED, CHE1, CHE2, E1}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** pulmonary embolism (MESH:D011655), atrial cardiomyopathy (MESH:D009202), stroke (MESH:D020521), arrhythmia (MESH:D001145), bleeding (MESH:D006470), hemorrhagic stroke (MESH:D000083302), diabetes mellitus (MESH:D003920), vascular disease (MESH:D014652), malignancy (MESH:D009369), atrial remodeling (MESH:D064752), injury to (MESH:D014947), Complications (MESH:D008107), inflammation (MESH:D007249), cardiometabolic dysfunction (MESH:D024821), syncope (MESH:D013575), Class III AADs (MESH:D008313), thromboembolic (MESH:D013923), PVI (MESH:D000071078), coronary artery disease (MESH:D003324), heart disease (MESH:D006331), transient ischemic attack (MESH:D002546), AAD (MESH:D000081015), congestive heart failure (MESH:D006333), AF (MESH:D001281), Ischemic strokes (MESH:D002544), hypertension (MESH:D006973), died (MESH:D003643), Symptom (MESH:D012816)
- **Chemicals:** antiarrhythmic medication (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943156/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12943156/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943156/full.md

---
Source: https://tomesphere.com/paper/PMC12943156